C4 Therapeutics Inc, a biotech company developing therapies to eliminate disease-causing proteins, has experienced a significant drop in stock price from a 52-week high of $7.22 to $2.56, highlighting the volatility and uncertainty of the biotech in…

C4 Therapeutics is a biotech company focused on developing early-stage therapies to eliminate disease-causing proteins, with a market capitalization of $115.74 million and a stock price of $1.62 per share as of May 4, 2025.

C4 Therapeutics Inc. is facing significant financial challenges and a decline in stock price, raising questions about its ability to deliver on its ambitious promises and translate its innovative therapies into financial success.